Use of plasma in preparing medicine for improving or treating cerebral infarction and cerebral edema

Through intermittent plasma inhalation device, intermittent plasma intervention is used to solve the problem of difficult plasma treatment dose control in the prior art, significantly improving the treatment effect of stroke and delaying cerebral ischemia The injury progresses and reduces cerebral edema.

CN113633893BActive Publication Date: 2024-11-01BEIJING BEIZHUO MEDICAL TECH DEV CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110962884.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-08-20
Publication Date
2024-11-01
Estimated Expiration
2041-08-20

AI Technical Summary

Technical Problem

Existing plasma therapy instruments have problems of difficulty in dose control and low safety in the treatment of neurological diseases, resulting in poor treatment effect on patients with ischemic stroke.

Method used

By using an intermittent plasma suction device, by controlling the release time, interval time and gas flow of the plasma, an ultrapure helium plasma discharge device generates plasma under atmospheric pressure, and plasma is inhaled in the nasal cavity, intermittent intervention is made to delay brain deficiency. Progress of blood damage.

Benefits of technology

Effectively delay the progress of cerebral ischemic injury, improve the treatment effect of ischemic stroke, provide a safe and portable treatment method, avoid oxidative stress caused by plasma excessive, and significantly reduce cerebral infarction and cerebral edema. volume.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113633893B_ABST
    Figure CN113633893B_ABST
Patent Text Reader

Abstract

The present invention discloses the use of plasma in preparing drugs for improving or treating cerebral infarction and cerebral edema, and belongs to the field of medical technology. The present invention is the first to discover the new use of intermittent plasma in improving cerebral infarction and cerebral edema, which has the characteristics of uniformity, stability, and contact safety. By giving plasma inhalation intervention when ischemic stroke occurs, the therapeutic effect of the disease is improved; and the cerebral infarction volume of the experimental ischemic stroke rat disease model can be significantly reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to use of plasma in preparing medicines for improving or treating cerebral infarction and cerebral edema, and belongs to the technical field of medicines. Background Art

[0002] Stroke is a group of diseases characterized by local neurological dysfunction due to cerebral blood circulation disorders. It is currently the leading cause of death and disability among adults worldwide. Ischemic stroke is the most common type of stroke, accounting for 70%-80% of all strokes. The main cause is cerebral ischemic damage and nerve cell death caused by insufficient blood supply to the brain due to cerebrovascular disease. In my country, with the acceleration of the aging trend of the population and the change of people's lifestyle, the incidence and mortality of ischemic stroke have been increasing year by year, bringing a heavy burden to society and families. Therefore, the development of prevention, treatment and health care methods for ischemic stroke-related diseases has gradually become a hot topic in this field.

[0003] When an ischemic stroke occurs, the first choice of treatment is to perform thrombolytic therapy with tissue plasminogen activator (rtPA) to recanalize blocked blood vessels and restore cerebral blood flow. For every minute of prolonged cerebral ischemic injury, up to millions of brain cells will die irreversibly, which will have an unpredictable impact on the patient's prognosis. With the development of medical technology, the "time window" for ischemic stroke treatment can be extended to 3-4.5 hours, and even to 6 hours in some cases. However, due to the irreversibility of nerve cell death, many patients have undergone thrombolytic therapy, but the effect is still poor, often accompanied by serious "sequelae", such as aphasia, hemiplegia, etc., which seriously affects the quality of life of patients and their families and causes a series of family and social problems. Therefore, when an ischemic stroke occurs, it is important to take certain measures to delay the "erosion" of the core area of ​​cerebral ischemia to the surrounding normal brain tissue and buy time for thrombolytic therapy, which is of great significance to improving the final treatment effect.

[0004] In recent years, the application of low-temperature plasma technology in the biomedical field has become an emerging research hotspot and has thus developed into a new discipline - plasma medicine. 2- 、NO - and N 3-Plasma is widely used in sterilization, skin disease treatment, tumor treatment, oral medicine and wound healing. The authorized Chinese invention patent (ZL201511009739.X) discloses a method for protecting nerve cells, which discloses the protective effect of plasma on nerve cell damage in vitro. It should be noted that the patent found that plasma pretreatment has a protective effect on SH-SY5Y nerve cells damaged by H2O2 oxidative stress in vitro. The present invention precisely controls the parameters of plasma generation and treatment, optimizes the interval and treatment conditions of plasma nasal inhalation, so that the plasma acting on the human body is always at a physiological concentration. Based on the physiological characteristics of plasma, intervention is given after the onset of ischemic stroke, thereby delaying the progression of cerebral ischemic damage and improving the final treatment effect.

[0005] However, in the past, the development of plasma therapy equipment was often limited to sterilization, tumor treatment, and skin disease treatment, which requires a large amount of active substances produced by plasma. When this dose of plasma is directly inhaled by the human body, it will inevitably cause discomfort and even worsen the progression of the disease due to lack of oxygen. How to control the dose of plasma and develop a plasma device for the treatment of neurological diseases that is simple, convenient, and safe is an urgent problem to be solved. Summary of the invention

[0006] The purpose of the invention is to provide a new use of intermittent plasma inhalation in improving cerebral infarction and cerebral edema.

[0007] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0008] Use of plasma in preparing medicine for improving or treating cerebral infarction and cerebral edema.

[0009] The plasma is one or more of low-temperature plasma, atmospheric pressure plasma, and helium discharge plasma.

[0010] The plasma is a batch plasma.

[0011] The intermittent plasma refers to the preparation of several independent plasma release units, or the continuous generation of plasma is intervened in an intermittent manner, each plasma intermittent intervention is regarded as an independent intervention unit, and a complete process requires the use of 12-20 intervention units.

[0012] The plasma reaction gas is ultrapure helium with a purity of 99.999%; the discharge driving voltage is 5.6 kilovolts and the frequency is 5000 Hz sinusoidal alternating current. Each intervention unit includes a plasma release time of 5-20 seconds and an interval time of 5-20 seconds.

[0013] There is a time interval of 1-30 seconds, preferably 5-20 seconds, between each plasma intervention unit.

[0014] The plasma used for the treatment of ischemic stroke in the embodiment of the present invention is generated by a plasma discharge device, which does not require a low-pressure environment and can directly generate plasma under atmospheric pressure conditions. It can be used to improve the treatment effect of ischemic stroke. After the plasma is inhaled into the nasal cavity, the active particles in the plasma can reach the "penumbra" around the stroke brain injury area through the circulatory system or the blood-brain barrier behind the nasal cavity, thereby delaying the progression of brain damage and improving the treatment effect. The present invention provides a plasma discharge device, which has the following advantages:

[0015] 1. The plasma generator is simple to manufacture, easy to disassemble and replace electrodes, and portable and movable.

[0016] 2. The macroscopic temperature of the plasma beam generated is close to normal temperature and has almost no damage to normal cells or biological tissues.

[0017] 3. Plasma contains active substances that can have beneficial effects on the nervous system. Intervention by inhaling atmospheric pressure plasma through the nasal cavity provides new ideas and means for the treatment of neurological diseases.

[0018] In addition to the above-mentioned plasma discharge devices, other devices having the function of generating and / or storing plasma discharge can also be used.

[0019] It should be noted that the present invention is the first to discover and prove the use of plasma as a drug for cerebral ischemia and cerebral infarction. Plasma contains a large amount of active oxygen and active nitrogen components. The present invention uses intermittent plasma inhalation to ensure the effect of plasma and control the amount of plasma, so as not to cause oxidative / nitrogenic stress and damage caused by a large amount of plasma, thereby utilizing the physiological characteristics of plasma and proving its therapeutic effect on cerebral infarction and cerebral edema.

[0020] In previous animal experiments, animals were given continuous plasma inhalation, but they would soon suffocate and die. The present invention creatively discovered that intermittent administration of the drug avoids suffocation in animals and unexpectedly has a definite therapeutic effect.

[0021] In the animal stroke disease model experiment, 5 seconds of plasma inhalation with an interval of 5 seconds had a very good effect. This patent prefers intermittent inhalation intervention.

[0022] Based on animal experiments, the recommended reference interval for human dosage is: 20 seconds of inhalation, 10 seconds of interval, and 5 minutes of duration. The specific dosage should be optimized according to the patient's condition, that is, to ensure the maximum amount of inhalation without causing discomfort to the patient.

[0023] In addition, in some embodiments of the present invention, a time control module is provided to synchronously control the power supply and gas supply of the plasma generator. By adjusting the time mode, plasma can be generated intermittently at a fixed time, so that the patient can alternately inhale plasma and air, thereby preventing the discomfort caused by long-term uninterrupted inhalation of plasma.

[0024] Furthermore, in some embodiments of the present invention, the plasma intensity and the concentration of active substances can be controlled by adjusting the power supply parameters (such as voltage, voltage frequency) and gas flow rate, and different intervention intensities can be selected according to the severity of the nervous system disease to achieve customized treatment, thereby enhancing the application flexibility of the device.

[0025] Additional advantages, purposes, and features of the present invention will be described in part in the following description, and will become apparent to those skilled in the art after studying the following, or may be learned from the practice of the present invention. The purposes and other advantages of the present invention may be realized and obtained by the structures specifically pointed out in the written description and its accompanying drawings.

[0026] Those skilled in the art will appreciate that the objectives and advantages that can be achieved with the present invention are not limited to the above specific description, and the above and other objectives that can be achieved by the present invention will be more clearly understood from the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] The drawings described herein are used to provide a further understanding of the present invention, constitute a part of this application, and do not constitute a limitation of the present invention.

[0028] Figure 1 This is an overall structural diagram of an intermittent plasma discharge device provided in Example 1 of the present invention.

[0029] Figure 2 This is a schematic diagram of the structure of the gas / circuit controller in Example 1 of the present invention.

[0030] Figure 3 Schematic diagram of the structure of the gas control module of the gas / circuit controller in Example 1 of the present invention.

[0031] Figure 4 Schematic diagram of the structure of the plasma generator in Example 1 of the present invention.

[0032] Figure 5 This is a schematic diagram of the control panel structure of the gas / circuit controller in Example 1 of the present invention.

[0033] Figure 6 Schematic diagram of the cross section of the insulating fixing sleeve of the plasma generator in Example 1 of the present invention.

[0034] Figure 7 The plasma discharge model machine made according to Example 1 of the present invention, as well as schematic operation and actual operation image examples of applying the device to ischemic stroke disease model rats.

[0035] Figure 8 The magnetic resonance apparent diffusion coefficient (ADC) imaging results of rats at various time points in Example 3 of the present invention are used to detect the cerebral infarction volume of the rats.

[0036] Fig. 9 For Figure 8 Statistical analysis of infarct volume in rats showed that plasma intervention could significantly reduce infarct volume.

[0037] Fig.10 The magnetic resonance T2 sequence imaging results of rats in each group 48 hours later were used to detect the volume of brain edema in rats.

[0038] Fig.11 For Fig.10 The statistical analysis results of brain edema volume in rats showed that plasma intervention could reduce brain edema volume. DETAILED DESCRIPTION

[0039] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments and the accompanying drawings. Here, the illustrative embodiments of the present invention and their descriptions are used to explain the present invention, but are not intended to limit the present invention.

[0040] It should also be noted that, in order to avoid obscuring the present invention due to unnecessary details, only structures and / or processing steps closely related to the solutions according to the present invention are shown in the accompanying drawings, while other details that are not closely related to the present invention are omitted.

[0041] It should be emphasized that the term “include / comprises” when used herein refers to the presence of features, elements, steps or components, but does not exclude the presence or addition of one or more other features, elements, steps or components.

[0042] Example 1 Intermittent plasma discharge device

[0043] like Figure 1FIG. 1 is a plasma device for treating nervous system diseases provided by an embodiment of the present invention, the device comprising: a gas cylinder 1, a gas / circuit controller 2 and a plasma generator 3. Figure 1 The gas cylinder 1 in the example is a high-purity gas cylinder, which may store helium or argon. The gas cylinder 1 is connected to the gas / circuit controller 2 via a first gas pipe 41, and the gas / circuit controller 2 is connected to the plasma generator 3 via a second gas pipe 42, a high-voltage line 43, and a ground line 44. In the embodiment of the present invention, the term "high-voltage line" refers to a line that outputs a relatively high voltage relative to the ground line, and is not used to limit the voltage applied to the high-voltage line to a voltage above 10Kv. In the embodiment of the present invention, the value of the voltage applied to the high-voltage line is generally in the range of 0-10kV.

[0044] like Figure 2 As shown, the gas / circuit controller 2 includes a power supply control module 21, a gas control module 22 and an electrical parameter module 23, and may also include a control panel ( Figure 2). The power supply control module 21 may include a regulating power supply 211 and a time control module 212, wherein the regulating power supply 211 is connected to the plasma generator 3 via the high-voltage line 43 and the ground line 44 to provide the plasma generator 3 with a voltage to be applied between its metal electrodes, so as to generate a plasma jet by utilizing the discharge of the metal electrodes and the gas input into the plasma generator 3 by the gas control module. The voltage output by the regulating power supply 211 may be a constant voltage or a pulse voltage. The regulating power supply 211 may be provided with a voltage gear regulator and a frequency gear regulator. The voltage gear regulator is used to connect the voltage value on the high-voltage line 43, and the frequency gear regulator is used to adjust the frequency of the output voltage. By adjusting the voltage and frequency applied to the plasma generator, the discharge intensity between the metal electrodes of the plasma generator 3 and the length of the plasma jet (the discharge duration of the metal electrodes) can be controlled. The time control module 212 may include a control mainboard and a logic circuit, which is used to provide a synchronous control signal to the gas control module 22 and the plasma generator 3 via the logic circuit under the control of the control mainboard, that is, the output end of the time control module 212 is connected to both the gas control module 22 and the plasma generator 3, and is used to control the power supply and gas supply, and the power off and gas off synchronization of the plasma generator 3. In an embodiment of the present invention, the plasma generator 3 can work in a set time mode, and the time mode (or discharge mode) may include an intermittent mode and a continuous mode. The intermittent mode is used to intermittently provide high voltage to the plasma generator, and the continuous mode is used to continuously provide high voltage to the plasma generator. In an embodiment of the invention, the control panel can be used to set or adjust parameters such as the time mode, voltage, frequency, gas flow rate and total discharge time. The discharge intensity of the metal electrode can be controlled by adjusting the voltage and frequency applied between the metal electrodes and the gas flow rate output by the gas control module. The plasma generator 3 can be controlled to perform intermittent or continuous discharge at regular intervals by adjusting the time mode and the discharge duration.

[0045] like Figure 3 As shown, the gas control module 22 includes a gas flow meter 221, a control chip 222 and a pneumatic solenoid valve 223. Specifically, as Figure 3 As shown, one end of the gas flow meter 221 of the gas control module 22 is connected to the gas cylinder 1 through the first gas pipe 41, and the other end is connected to the gas inlet of the pneumatic solenoid valve 223 for adjusting the gas flow, and the gas outlet of the pneumatic solenoid valve 223 is connected to the gas inlet 36 of the plasma generator 3 through the second gas pipe 42. The input end of the control chip 222 is connected to the time control module 212, and the output end is connected to the pneumatic solenoid valve 223. The gas outlet of the pneumatic solenoid valve 223 is controlled to be opened or closed by identifying the synchronous control signal output by the time control module 212.

[0046] like Figure 4As shown, the plasma generator 3 may include an insulating shell 31, a first metal electrode 32, a second metal electrode 33, an insulating medium tube 34, an insulating fixed sleeve 35 and an air inlet 36. The first metal electrode 32, the second metal electrode 33, the insulating medium tube 34 and the insulating fixed sleeve 35 may be encapsulated in the insulating shell 31. The insulating shell 31 may be designed to be handheld, so that the entire plasma generator 3 is small and portable and can be handheld. In one embodiment, the insulating shell 31 of the plasma generator may be designed to be cylindrical, but the present invention is not limited thereto, and may also be other shapes that are convenient for handholding and / or convenient for other components to be encapsulated therein. The gas cylinder 1 is used to supply gas to the plasma generator 3, and the gas / circuit controller 2 is used to adjust the discharge parameters such as gas flow, voltage, and voltage signal frequency to control the discharge intensity of the plasma generator 3, and the power supply and gas supply are synchronously controlled by the power supply control module 21 and the gas control module 22 to control the discharge time of the plasma generator 3. In addition, the electrical parameter module 23 is connected to the power supply control module 21 and the gas control module 22 . The discharge parameters of the plasma generator 3 can be monitored through the electrical parameter module 23 , so that the discharge state of the plasma generator 3 can be monitored.

[0047] like Figure 4 As shown, the insulating shell 31 is also provided with a nozzle flush with the end of the insulating medium tube 34. The plasma jet is generated between the first metal electrode 32 and the second metal electrode 33 of the plasma generator, propagates toward the end of the insulating medium tube 34 and is ejected from the nozzle of the insulating shell 31.

[0048] In one embodiment of the present invention, the power supply control module 21 is connected to the high voltage line 43 and the ground line 44 passing through the insulating shell 31 of the plasma generator 3 via the electrical parameter module 23, and the high voltage line 43 and the ground line 44 are respectively connected to the first metal electrode 32 and the second metal electrode 33, so as to generate a high voltage for generating plasma between the first metal electrode 32 and the second metal electrode 33. The first metal electrode 32 is placed inside the insulating medium tube 34, and the second metal electrode 33 is coated on the outer wall of the insulating medium tube 34. The first metal electrode 32 and the second metal electrode 33 pass through the insulating shell 31 through the high voltage line 43 and the ground line 44 to connect the power supply control module 21 and the electrical parameter module 23.

[0049] In some embodiments of the present invention, the electrical parameter module 23 is composed of some meters related to voltage, voltage output frequency, gas flow, etc., which are used to monitor the discharge state of plasma based on the numerical values ​​of each meter, and help determine whether the various parameters of plasma are abnormal or up to standard during the plasma intervention process, thereby maintaining the safety and accuracy of treatment.

[0050] Specifically, Figure 5As shown, the gas / circuit controller 2 is controlled through a control panel 24, on which a circuit master switch (master power switch) 241, a voltage adjustment knob 242, a frequency adjustment knob 243, a gas flow adjustment knob 244 and a time control mainboard 245 are provided. The time control mainboard 245 includes an electronic display screen 2451, an "hour" selection button 2452, a "minute" selection button 2453, a "second" selection button 2454 and a time mode selection button 2455. The circuit master switch 241 is used to control the on and off of the entire circuit. The voltage adjustment knob 242, the frequency adjustment knob 243 and the gas flow adjustment knob 244 are respectively used to adjust the voltage, voltage frequency and gas flow provided to the plasma generator 3. The electronic display screen 2451 is used to display the selected time to indicate the total discharge duration; the "hour" selection button 2452, the "minute" selection button 2453 and the "second" selection button 2454 are used to select the "hour", "minute" and "second" of the time. The time mode selection button 2455 is used to select intermittent mode or continuous mode.

[0051] Specifically, Figure 6 As shown, a group of through holes arranged along the axial direction may be provided in the insulating fixed sleeve 35 of the plasma generator 3. For example, the insulating fixed sleeve 35 may include a first through hole 351 and a second through hole 352. The first through hole 351 and the second through hole 352 may be coaxial, but have different apertures. The aperture of the first through hole 351 is slightly larger than the diameter of the first metal electrode 32, and is used to insert and fix the first metal electrode 32. The aperture of the second through hole 352 is slightly larger than the diameter of the insulating medium tube 34, and is used to insert and fix the insulating medium tube 34. In addition, a third through hole 353 may be provided on the side of the insulating fixed sleeve 35 along the vertical axis. The third through hole 353 is bonded to the air inlet 36 and is used to pass gas into the insulating medium tube 34. In one embodiment of the present invention, the air inlet 36 may be designed to be in a pagoda shape to ensure good sealing when connecting the air pipe, but the present invention is not limited thereto, and may also be in other shapes.

[0052] After the insulating medium tube 34 is inserted into the second through hole 352 and fixed, the first metal electrode 32 is inserted into the insulating medium tube 34 through the first through hole 351 and the second through hole 352, and the second metal electrode 33 is tightly bonded to the outer wall of the insulating medium tube 34 at a distance from the first metal electrode 32, and plasma is generated between the first metal electrode 32 and the second metal electrode 33 and ejected from the end of the insulating medium tube 34 to the outside of the nozzle of the insulating shell 31. In some embodiments of the present invention, the first metal electrode 32 and the second metal electrode 33 can be made of a stainless steel needle and an aluminum foil ring, respectively, and the insulating medium tube 34 can be made of a quartz glass tube, and the discharge mode used between the first metal electrode 32 and the second metal electrode 33 is a needle-ring dielectric barrier discharge. Here, the materials of the first metal electrode 32, the second metal electrode 33 and the insulating medium tube 34 are only examples, and the present invention is not limited thereto. The first metal electrode 32 and the second metal electrode 33 can also be made of other metal electrode materials, and the insulating medium tube 34 can also be other hard insulating media.

[0053] The steps of using the plasma generator 3 of this embodiment are as follows: gas is introduced into the plasma generator 3 through the gas cylinder 1 and the gas control module 22, for example, gas is introduced into the insulating fixed sleeve 35 of the plasma generator 3, the main circuit switch 241 is turned on through the control panel 24 of the gas / circuit controller 2, the voltage applied between the first metal electrode 32 and the second metal electrode 33, the frequency of the voltage output and the gas flow rate, etc. are adjusted, the plasma generation time is set through the "hour" selection button 2452, the "minute" selection button 2453 and the "second" selection button 2454, and the time mode is set to the intermittent mode through the time mode selection button 2455. The time control module controls based on the time and time mode set through the control panel, so that a plasma jet is intermittently generated at the nozzle of the insulating shell 31 of the plasma generator 3, and the patient can be intermittently inhaled by aligning the nasal cavity with the plasma jet. Under the control of the time control module 212, when the plasma generator 3 is powered and supplied with gas, the patient inhales the plasma jet, and when the plasma generator 3 is powered off and supplied with gas, the patient inhales air, and this is repeated (for example, plasma inhalation for 5 seconds, stop for 5 seconds, normal breathing of air, and this is repeated for 2 minutes). During the intervention process, the electrical parameter module 23 monitors the plasma discharge state in real time. After the intervention is completed, the power supply control module 21 automatically cuts off the power, and the plasma beam stops generating. In the present invention, the macroscopic temperature of the generated plasma beam is close to room temperature, and there is almost no damage to normal cells or biological tissues.

[0054] The intermittent plasma discharge device of the embodiment of the present invention is small in size, simple to manufacture, easy to disassemble and replace electrodes, and portable and movable.

[0055] In addition, in some embodiments of the present invention, the atmospheric pressure plasma contains active substances that can have a beneficial effect on the nervous system, and intervention is performed by inhaling the atmospheric pressure plasma through the nasal cavity, which provides new ideas and means for the treatment of nervous system diseases.

[0056] Furthermore, in some embodiments of the present invention, since a time control module is provided to synchronously control the power supply and gas supply of the plasma generator, plasma can be generated intermittently at a fixed time by adjusting the time mode, so that the patient can alternately inhale plasma and air, thereby preventing discomfort caused by long-term uninterrupted inhalation of plasma.

[0057] Furthermore, in some embodiments of the present invention, the plasma intensity and the concentration of active substances are controlled by adjusting the power supply parameters and the gas flow rate, and different intervention intensities can be selected according to the degree of cerebral ischemia to achieve customized treatment, thereby enhancing the flexibility of the device.

[0058] Example 2 Plasma discharge device

[0059] A needle-ring dielectric barrier discharge structure is adopted, a quartz glass tube is used as the dielectric tube, a stainless steel needle with an inner diameter of 1 mm, an outer diameter of 3 mm, and a curvature radius of about 0.05 mm is used as the high-voltage electrode, and a ground electrode is formed by winding a 2 mm wide aluminum foil outside the quartz tube. The distance from the needle tip to the ground electrode and the distance from the ground electrode to the tube mouth are 10 mm; the driving voltage is 5.6 kV, the frequency is 5000 Hz, and ultrapure helium (99.999%) is used for discharge. The device of this embodiment can also be used for the experiment of embodiment 3.

[0060] Example 3 New use of intermittent plasma inhalation in improving cerebral infarction and cerebral edema

[0061] 1. Experimental Materials

[0062] 1. Plasma discharge device: The plasma discharge device prepared in Example 1 was applied to the intervention experiment of rat cerebral ischemia model.

[0063] 2. Experimental animals: Adult male SD rats, weighing 200-220g, were purchased and placed in polypropylene cages, raised in a 12-h light-dark alternating environment, and allowed to freely take food and water. The rats were randomly divided into a sham operation group (only surgery, no embolization of blood vessels, for control), a model group, and a plasma inhalation group, with 6 rats in each group. The experimental process followed the 3R principle to reduce the number of animals used and animal suffering.

[0064] 2. Experimental Methods

[0065] 1. Establishment of rat middle cerebral artery occlusion (MCAO) model:

[0066] The rat middle cerebral artery occlusion (MCAO) model was constructed by thread embolization, and the ischemic stroke disease model was constructed. The specific operation was as follows: intraperitoneal injection of 100mg / kg+10mg / kg ketamine+xylazine for anesthesia. After successful anesthesia, the SD rats were incised in the midline of the neck, the superficial muscles and fascia were separated to find the common carotid artery, the blood vessels at the bifurcation of the common carotid artery were stripped, and part of the common carotid artery, external carotid artery, and internal carotid artery were freed. The artery clamps were used to ligate both ends of the external carotid artery. A small incision was made with ophthalmic surgical scissors in the middle of the ligation, and a 0.38mm silicone-coated thread was prepared. The thread was held with ophthalmic forceps and passed through the external carotid artery and the common carotid artery. The embolus was pushed into the bifurcation of the internal carotid artery and the external carotid artery and transferred to the appropriate position of the internal carotid artery to complete the MCAO model. The artery clamp was released and the incision was sutured.

[0067] MRI was performed 45 minutes after modeling to determine whether the model was successfully constructed.

[0068] 2. Medication intervention:

[0069] Select rats with successful model establishment and Figure 7 The method shown uses plasma nasal inhalation as an intervention.

[0070] After 60 minutes of ischemia (the timing starts after the suture plug is successfully inserted into the designated position of the blood vessel), plasma intermittent inhalation intervention was given ( Figure 7 ), the specific intervention method was plasma inhalation for 5 seconds, stop for 5 seconds, repeated, the whole process lasted for 2 minutes, and magnetic resonance imaging was performed on the rats 15 minutes after the intervention to evaluate the short-term effect of the intervention. 90 minutes after modeling, the rats were anesthetized, the embolus was removed, and the blood supply was restored to simulate the vascular recanalization process after stroke treatment. The rats continued to be raised normally for 24 hours to observe the final effect, and magnetic resonance imaging and brain tissue TTC (2,3,5-triphenyltetrazolium chloride) staining were performed on the rats.

[0071] 3. Experimental Results

[0072] Figure 8 and Fig. 9 The results showed that after plasma treatment, the volume of cerebral ischemia can be reduced in the short term, and the spread of cerebral ischemic damage area can be significantly reduced; 24 hours after vascular recanalization, TTC staining and magnetic resonance images showed that plasma treatment significantly reduced the volume of cerebral infarction, and plasma treatment can significantly improve the treatment effect.

[0073] Fig.10 and Fig.11The results showed that brain edema was most severe 48 hours after cerebral infarction, so the rats in each group were kept for another 48 hours before MRI examination. The results are shown in the figure below, which shows the T2WI sequence magnetic resonance images of rats in each group. The light-colored areas are the areas of brain edema. The rats in the MCAO model group had obvious brain edema, and the median line of the brain was significantly shifted. After plasma intervention, the brain edema of the rats was significantly reduced.

[0074] The parameters in this model example are only examples and are not intended to limit the present invention. Different parameters for different patients and appropriate parameters for severe conditions are determined based on clinical trials, etc.

[0075] It should be clear that the present invention is not limited to the specific configuration and processing described above and shown in the figures. For the sake of simplicity, a detailed description of the known method is omitted here. In the above embodiments, several specific steps are described and shown as examples. However, the method process of the present invention is not limited to the specific steps described and shown, and those skilled in the art can make various changes, modifications and additions, or change the order between the steps after understanding the spirit of the present invention.

[0076] It should be noted that the exemplary embodiments mentioned in the present invention describe some methods or systems based on a series of steps or devices. However, the present invention is not limited to the order of the above steps, that is, the steps can be performed in the order mentioned in the embodiments, or in a different order from the embodiments, or several steps can be performed simultaneously.

[0077] In the present invention, features described and / or illustrated for one embodiment may be used in the same or similar manner in one or more other embodiments, and / or combined with features of other embodiments or replace features of other embodiments.

[0078] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the embodiments of the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of intermittent plasma in the preparation of drugs for improving or treating cerebral infarction and cerebral edema; The intermittent plasma refers to preparing a plurality of independent plasma release units, or intervening the continuously generated plasma in an intermittent manner, each plasma intermittent intervention is regarded as an independent intervention unit, and a complete process requires the use of 12-20 intervention units; The plasma reaction gas is ultrapure helium with a purity of 99.999%; the discharge driving voltage is 5.6 kilovolts and the frequency is 5000 Hz of sinusoidal alternating current; each intervention unit includes a plasma release time of 5-20 seconds and an interval time of 5-20 seconds.

2. The use according to claim 1, characterized in that: There is a time interval of 1 to 30 seconds between each plasma providing unit.